Anti-Human PD-L1 Polyclonal Antibody (HV974014)

Name: Anti-Human PD-L1 Polyclonal Antibody
Brand: abinScience
SKU: HV974014
Price: 168 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

50ug
100ug

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号

HV974014

説明

Anti-CD274/PD-L1/B7-H1 Polyclonal Antibody (HV974014) is a rabbit polyclonal antibody detecting B7-H1 in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

種反応性

Human

アプリケーション

ELISA, IHC, WB

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

免疫原

E. coli - derived recombinant Human CD274/PD-L1/B7-H1 (Phe19-Arg238).

ターゲット

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

エンドトキシンレベル

Please contact with the lab for this information.

純度

>90% as determined by SDS-PAGE.

精製

Purified by antigen affinity column.

アクセッション番号

Q9NZQ7

形態

Liquid

保存バッファー

0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

製品使用情報

アプリケーション	希釈
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

安定性と保存

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

背景

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

注意事項

For research use only.

イメージ

参考文献

データシート